Compare HTZ & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | OABI |
|---|---|---|
| Founded | 1918 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.1M | 696.4M |
| IPO Year | 2021 | 2021 |
| Metric | HTZ | OABI |
|---|---|---|
| Price | $1.74 | $4.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $2.13 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 14.6M | 1.2M |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | 6.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,504,000,000.00 | $18,666,000.00 |
| Revenue This Year | $8.06 | $87.73 |
| Revenue Next Year | $3.95 | $25.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.45 | $1.32 |
| 52 Week High | $8.18 | $5.43 |
| Indicator | HTZ | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 50.63 |
| Support Level | $1.67 | $1.93 |
| Resistance Level | $2.34 | $5.06 |
| Average True Range (ATR) | 0.15 | 0.33 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 17.69 | 44.64 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.